《《《《《《《《内容已删除》》》》》》》》》

大家在查：杨义特征性中锰欧米咖店掌柜 IntelXeonMP 10月4日迪•伊叶连娜 stereoplasm

伊马替

伊马替

伊马替

伊马替

1

Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib .

有研究表明与伊马替尼相比，尼罗替尼是一种更强效的 BCR-ABL 抑制剂。

2

4

The next step , says Jiang is finding a drug that blocks AHI-1, which could potentially be given in combination with imatinib in the future .

江表示，下一步是找一种阻滞 AHI-1 的药物，这种药物可能在将来与伊马替尼联用于治疗。

5

The estimated overall survival rate for patients receiving Gleevec was 88% when considering deaths from all causes .

在进行死因分析时，接受伊马替尼治疗的患者的总体生存率为 88%。

7

Imatinib was re introduced in patients who had molecular relapse .

出现分子学复发的患者，再次应用伊马替尼。

10

OBJECTIVE To study and improve the synthesis of imatinib mesylate .

目的研究和改进甲磺酸伊马替尼的合成工艺。

11

Clinical Study of Chinese Gastrointestinal Stromal Tumors Patients Treated with Imatinib Mesylate

甲磺酸伊马替尼治疗国人胃肠间质瘤的临床研究

12

Resistance in the treatment for chronic myelogenous leukemia with imatinib and its management

伊马替尼治疗慢性粒细胞白血病的耐药与对策

13

Efficacy and safety evaluation of imatinib in the treatment of patients with chronic granulocytic leukemia in accelerated phase

伊马替尼治疗慢性粒细胞白血病加速期疗效评价

17

Mechanism and strategy against Imatinib-resistant chronic myeloid leukemia

慢性粒细胞白血病伊马替尼耐药性的机制与对策

18

Clinical observation on the effects of low dosage imatinib to chronic myelogenous leukemia in blast crisis

小剂量伊马替尼治疗慢性髓细胞白血病急变期患者的临床疗效

20

Clinical Evaluation of Imatinib Mesylate in the treatment of Blast-Phrase Chronic Myeloid Leukemia

甲磺酸伊马替尼治疗慢性粒细胞白血病急变期的疗效分析

热词推荐

大家在看